TRex Bio

TRXB
12.3309.80% ( -1.340 )
Trading: Nov 16, 12:43:08 (EDT)

Financials

Q3 FY2026 EarningsQ3 FY26 net loss of $13.2M beat the consensus mean of $15.1M, primarily driven by lower-than-anticipated operating expenses despite a significant YoY ramp in clinical activity. Revenue remained flat at $0 as expected for this clinical-stage biotech. The successful October IPO raised $119M in net proceeds, extending the cash runway into H2 2029, while key Phase 1b data for TRB-061 remains on track for mid-2027.

Financial report interval: 2026.06.30 - 2026.09.30

Overview: TRex Bio(TRXB) the EBIT is -13.92 M (--%), Beat estimate;the EPS is -10.06 (--%), Miss estimate.

Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITExceed expectations
-0.01B--
-0.02B--
+0.00B--%
EPSMiss expectations
-10.06--
-2.7206--
-7.3394--%

Upcoming earnings report - FY2026 Q3 Earning Release

Available dateDec 18, 2026
Estimate Revenue0
Estimate EBIT-15.81 M
Estimate EPS-2.7205

Revenue

ActualEstimateUnit: USD
Quarterly

EBIT

ActualEstimateUnit: USD
Quarterly

Net income

ActualEstimateUnit: USD
Quarterly

EPS

ActualEstimateUnit: USD
Quarterly